Clinical Trials Directory

Trials / Unknown

UnknownNCT03635827

Xenon Inhalation for Treatment of Posttraumatic Stress Disorder

A Double-Blind, Randomized, Placebo-Controlled Trial of Xenon Inhalation for Treatment of Patients With Posttraumatic Stress Disorder

Status
Unknown
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
190 (estimated)
Sponsor
Nobilis Therapeutics Inc. · Industry
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

This study is a double-blind, randomized, placebo-controlled, clinical trial in parallel groups in patients with PTSD.

Conditions

Interventions

TypeNameDescription
COMBINATION_PRODUCTNBTX-001 Xenon InhalerThe NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.
COMBINATION_PRODUCTPlaceboThe placebo medical gas consists of 30% oxygen and 70% nitrogen.The dose of placebo medical gas is 10 L by volume.

Timeline

Start date
2021-06-01
Primary completion
2021-06-01
Completion
2021-07-01
First posted
2018-08-17
Last updated
2021-03-03

Regulatory

Source: ClinicalTrials.gov record NCT03635827. Inclusion in this directory is not an endorsement.